GOHEALTHCARE SPECIALTY REVENUE CYCLE MANAGEMENT

A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine

A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine: specialty-specific payer workflows, reimbursement, denials, compliance, coding, A/R and revenue protection from GoHealthcare Practice Solutions.

Developed by GoHealthcare Practice Solutions
Expert Review: Pinky Maniri, MSc
CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF
Certified in Healthcare A.I. Governance
CEO & Founder

Request an RCM Assessment View Orthobiologics & Regenerative MSK Medicine RCM

A/R & UNDERPAYMENT RECOVERY

Accounts receivable is not an aging report. It is a work inventory. Every open balance should have a reason, owner, next action and deadline. Underpayment recovery adds another layer: a paid claim must be compared with what the payer should have paid.

SPECIALTY CONTEXT

Orthobiologics RCM begins with a question that traditional billing teams often skip: is the service covered at all? Evidence status, FDA/regulatory status, payer medical policy, coding and patient financial responsibility are separate issues and must be resolved before treatment.

REFERENCE YEAR

2026. Verify current payer policies, code sets, contracts, fee schedules, NCCI/MUE edits and jurisdiction-specific requirements.

Operational use: Built for physicians, executives, administrators, RCM leaders, prior authorization teams, coders, compliance professionals and specialty operations teams. The objective is compliant reimbursement performance, not aggressive billing.

DIRECT ANSWER

A/R & Underpayment Recovery

PRACTICAL RCM POINT

Revenue problems do not begin at the payer. They usually begin earlier in the workflow. The job of RCM leadership is to find the first defect, fix the account and then fix the process that created it.

SPECIALTY REALITY

Why Generic Billing Fails in This Specialty

Specialty Revenue Challenge	Why It Matters	Operational Control
Teams start with prior authorization instead of benefit status	A payer may classify the therapy as excluded or investigational, making standard PA an incomplete workflow.	Perform benefit and medical-policy investigation first.
Different biologic products are called the same thing	PRP, BMAC, cell/tissue products, amniotic products, exosomes and prolotherapy have different regulatory and coverage issues.	Identify the exact product/procedure before coding or financial communication.
A code is mistaken for coverage	The existence of a CPT/HCPCS or unlisted pathway does not make a therapy payable.	Separate coding availability from benefit coverage.
Self-pay is used without enough financial disclosure	Patients may believe insurance refusal is temporary or appealable when the plan has a clear exclusion.	Document the reason for noncoverage and patient financial responsibility.
Marketing claims create compliance exposure	Aggressive claims about regeneration or FDA status can contradict evidence/regulatory reality.	Audit website, consent and sales language.
PRP is frequently miscoded as a conventional injection	This can bypass payer policy and create false-claim risk.	Use accurate code/reporting pathway.
Product cost is not tied to refund/collection policy	High-cost products can create disputes when treatment is cancelled or denied.	Establish written financial and inventory controls.
Appeals target the wrong issue	A medical-necessity letter cannot necessarily overcome a contractual exclusion.	Classify denial as exclusion, investigational policy, medical necessity, coding or administrative defect.

Teams start with prior authorization instead of benefit status

A payer may classify the therapy as excluded or investigational, making standard PA an incomplete workflow. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Perform benefit and medical-policy investigation first. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Different biologic products are called the same thing

PRP, BMAC, cell/tissue products, amniotic products, exosomes and prolotherapy have different regulatory and coverage issues. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Identify the exact product/procedure before coding or financial communication. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

A code is mistaken for coverage

The existence of a CPT/HCPCS or unlisted pathway does not make a therapy payable. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Separate coding availability from benefit coverage. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Self-pay is used without enough financial disclosure

Patients may believe insurance refusal is temporary or appealable when the plan has a clear exclusion. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Document the reason for noncoverage and patient financial responsibility. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Marketing claims create compliance exposure

Aggressive claims about regeneration or FDA status can contradict evidence/regulatory reality. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Audit website, consent and sales language. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

PRP is frequently miscoded as a conventional injection

This can bypass payer policy and create false-claim risk. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Use accurate code/reporting pathway. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Product cost is not tied to refund/collection policy

High-cost products can create disputes when treatment is cancelled or denied. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Establish written financial and inventory controls. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Appeals target the wrong issue

A medical-necessity letter cannot necessarily overcome a contractual exclusion. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Classify denial as exclusion, investigational policy, medical necessity, coding or administrative defect. For A/R & Underpayment Recovery, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

SERVICE LINE

High-Value Services and Revenue Exposure

Specialty Service / Revenue Category	Primary Revenue-Cycle Risk	Core Control
PRP	Benefit policy and accurate Category III reporting.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
BMAC	Product/processing identification and payer policy.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Amniotic/placental products	Noncoverage/regulatory review.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Cellular therapies	FDA/payer policy and self-pay controls.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Exosome products	High regulatory and coverage caution.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Prolotherapy	Distinct evidence/coverage pathway.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Autologous protein solutions	Product-specific policy.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Surgical biologic augmentation	Primary surgery authorization does not guarantee biologic payment.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Cartilage/bone-healing adjuncts	Outcome and payer policy vary.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Spine/intradiscal regenerative services	Highly restrictive coverage and unlisted coding risk.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.

PRP

Benefit policy and accurate Category III reporting. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

BMAC

Product/processing identification and payer policy. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Amniotic/placental products

Noncoverage/regulatory review. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Cellular therapies

FDA/payer policy and self-pay controls. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Exosome products

High regulatory and coverage caution. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Prolotherapy

Distinct evidence/coverage pathway. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Autologous protein solutions

Product-specific policy. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Surgical biologic augmentation

Primary surgery authorization does not guarantee biologic payment. The a/r & underpayment recovery workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

AR SEGMENTATION

How to Segment Specialty A/R

Segment	Why It Needs Separate Management
High-dollar procedural	Faster senior escalation.
Authorization-related	Requires pre-service record review.
Medical-necessity appeal	Clinical evidence/policy workflow.
Underpayment	Contract variance workflow.
No response/payer delay	Status escalation.
Patient responsibility	Only after correct adjudication.
Credit balance	Overpayment/refund control.
Workers' compensation	Jurisdiction-specific follow-up.

EXPECTED ALLOWABLE

Building an Expected-Reimbursement Model

The model should use the actual payer contract or governing fee schedule, relevant multiple-procedure/component reductions, site-of-service logic, carve-outs and known contract amendments. The model does not need to be perfect on day one; it needs to be good enough to identify material variances for review.

REVENUE INTEGRITY

The Financial Control Chain

The strongest specialty RCM model treats revenue as a chain of dependent controls: patient access → eligibility/benefits → prior authorization → clinical documentation → coding → charge capture → claim submission → payment → denial/A/R → underpayment recovery → final reconciliation.

Every handoff can either protect or leak revenue. The purpose of this page is to make the controls visible enough that leadership can manage them instead of discovering defects after the payer refuses payment.

Control Point	What Must Be True
Patient access	Correct patient, payer, product, network and coordination-of-benefits information.
Authorization	The approval/benefit determination matches the actual service, provider, site, anatomy, units and dates where required.
Documentation	The medical record supports what was clinically performed and why.
Coding	Codes, modifiers and units accurately represent the documented work.
Claim	Correct entity, POS, payer route and required supporting data.
Payment	Remittance is compared with contract/fee schedule and expected allowed amount.
A/R	Every open balance has a reason, owner, next action and deadline.
Compliance	Unsupported payment is not pursued or retained.

DENIAL INTELLIGENCE

Denial Patterns That Matter

Denial / Payment Failure	Typical Cause	Resolution Principle
Experimental/investigational	Policy excludes or noncovers service.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Benefit exclusion	Contract does not include therapy.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Wrong code	Conventional injection code used for regenerative service.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Product not covered	Payer does not reimburse product separately.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
No authorization	Plan requires review even when coverage is uncertain.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Medical necessity	Patient-specific evidence does not meet plan threshold.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Claim edit/unlisted processing	Payer requires records/manual review.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Patient dispute/refund	Financial disclosure was unclear.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.

Experimental/investigational

Policy excludes or noncovers service. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Benefit exclusion

Contract does not include therapy. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Wrong code

Conventional injection code used for regenerative service. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Product not covered

Payer does not reimburse product separately. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

No authorization

Plan requires review even when coverage is uncertain. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Medical necessity

Patient-specific evidence does not meet plan threshold. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Claim edit/unlisted processing

Payer requires records/manual review. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

Patient dispute/refund

Financial disclosure was unclear. The resolution should match the cause. A correctable data defect needs correction. A medical-necessity denial needs patient-specific documentation and the controlling policy. An authorization defect needs authorization escalation. A contractual underpayment needs expected-allowable analysis. A benefit exclusion should not be handled as though it were a normal coding denial.

COMPLIANCE

Compliance Guardrails

Revenue optimization and compliance should reinforce each other. Accurate claims are easier to defend, easier to appeal and less likely to create recoupments or overpayments.

Do not code a noncovered regenerative service as a conventional covered injection.
Do not state a product is FDA approved unless that specific status is accurate.
Do not imply self-pay status means the treatment is proven.
Do not alter diagnosis to fit a policy.
Document product source/processing as appropriate.
Provide clear informed financial disclosure.
Monitor vendor marketing and inducement risk.
Investigate and return any overpayment caused by incorrect coding.

COMPLIANCE POINT

If the only way to make the claim pay is to make the coding less truthful, the strategy is wrong.

REIMBURSEMENT

How to Improve Legitimate Reimbursement

Compliant reimbursement optimization focuses on preventable leakage and payer performance. The priorities are to prevent avoidable denials, capture supported charges, maintain accurate documentation/coding, identify payer underpayments, resolve aged high-value accounts and stop recurring defects.

1. Perform benefit investigation before scheduling.

2. Maintain a product-specific policy matrix.

3. Use transparent self-pay financial workflows.

4. Audit all regenerative medicine marketing claims.

5. Create accurate coding pathways for PRP/unlisted services.

6. Track denials by exclusion vs investigational vs administrative cause.

7. Measure product cost, collection and refund exposure.

8. Keep outcome tracking to support evidence and patient communication.

9. Separate covered primary surgery from noncovered biologic adjunct.

10. Route regulatory questions to qualified compliance/legal/regulatory review.

KPI

Executive KPIs

KPI	Management Use
Benefit-verification completeness	Before scheduling.
Policy classification	Covered/excluded/investigational.
Self-pay collection accuracy	Quoted vs collected.
Refund/dispute rate	Financial clarity.
Coding exception rate	Unlisted/manual claims.
Denial mix	Policy vs administrative.
Product margin	After refunds/collection cost.
Outcome capture	PROM/safety follow-up.

Every KPI needs a definition, numerator/denominator where applicable, source system, owner and review cadence. The executive dashboard should allow drill-down by payer, provider, location, procedure/service family and root cause.

AUDIT

Specialty Audit Playbook

Use a risk-based sample rather than reviewing claims randomly. Select high-value services, high-denial payers, providers with recurring documentation defects, accounts over 90 days, frequent modifier use, unlisted codes and claims with large payment variances.

Audit Test 1

Trace one real Orthobiologics & Regenerative MSK Medicine account from scheduling through final payment. Confirm benefit/eligibility, authorization, documentation, coding, modifiers/units, claim routing, payer adjudication, payment posting and follow-up. Identify where the first defect occurred and whether the organization's current control would prevent the same defect on the next account.

Audit Test 2

Audit Test 3

Audit Test 4

Audit Test 5

Audit Test 6

Audit Test 7

Audit Test 8

COMMON QUESTIONS

Frequently Asked Questions

What does A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine mean operationally?

A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine requires the revenue-cycle team to identify the controlling rule, the case-specific facts and the downstream action.

What should be verified first for A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine?

Identify the payer or plan, jurisdiction, date of service, provider and setting, then verify the source that governs the question.

How is A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine different from a coding or coverage question?

Coverage, authorization, coding and reimbursement are related but separate decisions; the remedy depends on which decision is actually at issue.

What documentation should support A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine?

The record should support the clinical facts and service actually furnished without creating or inferring facts for billing purposes.

How should a denial or payment variance involving A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine be handled?

Classify the adverse result first, then correct, appeal or pursue a payment review according to the actual cause.

What should leadership monitor for A/R & Underpayment Recovery for Orthobiologics & Regenerative MSK Medicine?

Track exceptions, dollars affected, time to resolution, recurrence and concentration by payer, location or service category.

RELATED RESOURCES

Related GoHealthcare Specialty RCM Pages

GoHealthcare Resource	How It Connects	URL
Revenue Cycle Management	Primary GoHealthcare RCM flagship page.	https://www.gohealthcarellc.com/revenue-cycle-management.html
RCM Services for Orthobiologics & Regenerative MSK Medicine	Specialty RCM hub.	https://www.gohealthcarellc.com/rcm-services-orthobiologics-regenerative-msk-medicine.html
Full-Service RCM	Core managed RCM service.	https://www.gohealthcarellc.com/rcm-full-services.html
RCM Process	End-to-end operating workflow.	https://www.gohealthcarellc.com/revenue-cycle-management-process.html
Revenue Integrity	Revenue leakage, coding and compliance.	https://www.gohealthcarellc.com/revenue-integrity-msk-specialty-care.html
Prior Authorization Resource Center	Pre-service payer and medical-necessity operations.	https://www.gohealthcarellc.com/overview.html
Procedure Library	Procedure-specific clinical, coding and payer intelligence.	https://www.gohealthcarellc.com/procedure-library.html
Orthobiologics & Regenerative MSK Medicine Specialty Guide	Clinical and specialty operations reference.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medicine-specialty-hub.html
Medical Billing Services	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medical-billing-services.html
Medical Coding & Documentation	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medical-coding-documentation.html
Prior Authorization & Revenue Protection	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-prior-authorization-revenue-protection.html
Denial Management & Appeals	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-denial-management-appeals.html
A/R & Underpayment Recovery	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-accounts-receivable-underpayment-recovery.html
Revenue Integrity & Compliance	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-revenue-integrity-compliance.html
Reimbursement Optimization & RCM KPIs	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-reimbursement-optimization-rcm-kpis.html

REFERENCES

Authoritative References

Authority	Reference
Primary / Specialty Source	May 2026 Regenerative Medicine Warning https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products
Primary / Specialty Source	PRP MSK LCD example https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39058
Primary / Specialty Source	Amniotic/Placental MSK LCD example https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39879&ver=10
Primary / Specialty Source	General Compliance Program Guidance https://oig.hhs.gov/compliance/general-compliance-program-guidance/
Primary / Specialty Source	2026 Medicare Physician Fee Schedule https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
Primary / Specialty Source	2026 NCCI Policy Manual https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits/medicare-ncci-policy-manual
Primary / Specialty Source	CPT Licensing https://www.ama-assn.org/practice-management/cpt/cpt-licensing
Official Source	CMS MUE Program https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits/medicare-ncci-medically-unlikely-edits-mues

Find the revenue-cycle defects before they become aged A/R.

GoHealthcare can assess Orthobiologics & Regenerative MSK Medicine workflows across patient access, prior authorization, documentation, coding, claims, denials, A/R, underpayments and revenue integrity.

Request an RCM Assessment Return to Specialty RCM Hub

GOHEALTHCARE RCM AUTHORITY CENTER

Explore All 150 RCM Authority Pages

Move across the complete GoHealthcare MSK and Injury Revenue Cycle Management knowledge system: specialty RCM, medical billing and coding, coverage and reimbursement intelligence, injury cases, workers’ compensation, in-network and out-of-network RCM, and ancillary MSK services.

Revenue Cycle Management — Main Flagship Page

Ambulatory Surgery Centers

Hand & Upper Extremity

Interventional Pain Management

MSK Radiology & Diagnostic Imaging

Neuromodulation

Neurosurgery

Occupational Medicine / Workers’ Compensation MSK

Orthobiologics & Regenerative MSK Medicine

Orthopedic Surgery

Physical Medicine & Rehabilitation (PM&R)

Spine & Interventional Spine

Sports Medicine

Medical Billing, Coding & Reimbursement Intelligence

Injury Case RCM

In-Network & Out-of-Network RCM

Ancillary MSK RCM

ABOUT THE EXPERT REVIEWER

Pinky Maniri, MSc

CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF
Certified in Healthcare A.I. Governance
CEO & Founder, GoHealthcare Practice Solutions

Pinky Maniri is a healthcare operations and financial management executive with approximately 30 years of experience in revenue cycle management, prior authorization, payment and reimbursement, physician and ambulatory practice operations, healthcare finance, business intelligence, and MSK specialty healthcare operations.

HFMA Certified Professional in:

Physician Practice Management
Ambulatory Practice Management
Revenue Cycle Management
Payment & Reimbursement
Accounting & Finance
Business Intelligence
Healthcare A.I. Governance

Editorial Review Scope

This resource was developed by GoHealthcare Practice Solutions and reviewed for healthcare operations, revenue cycle, reimbursement, and operational accuracy. Coverage, coding, medical necessity, utilization management, payer policy, and reimbursement requirements may vary by payer, plan, jurisdiction, setting, and date of service. Current authoritative sources should be reviewed before applying information to a specific patient, claim, or reimbursement determination.

Professional, Coding & Reimbursement Disclaimer

This material is for general professional, operational and educational purposes only and is not medical, legal, regulatory, coding, billing, reimbursement, financial, payer-specific or contractual advice. Coverage requirements, utilization-management criteria, code sets, NCCI/MUE edits, payment methodologies, fee schedules, payer policies and contracts change. Organizations must verify current official sources, applicable payer contracts, CMS/MAC guidance, state requirements and licensed code sets before making operational, coding or reimbursement decisions. No authorization, payment, reimbursement, financial result or compliance outcome is guaranteed.